As Gilead Sciences has outperformed its sector peers recently, analysts remain highly optimistic about the stock’s prospects.
In the latest trading session, Gilead Sciences (GILD) closed at $147.83, marking a -1.46% move from the previous day.
TD Cowen 46th Annual Health Care Conference March 3, 2026 11:10 AM ESTCompany ParticipantsJohanna Mercier - Chief ...
The average one-year price target for Gilead Sciences (NasdaqGS:GILD) has been revised to $159.01 / share. This is an ...
Zacks Investment Research on MSN
GILD to acquire ACLX for $7.8B & gain full control of Anito-Cel
Gilead Sciences, Inc. GILD announced that it will acquire a clinical-stage biotechnology company, Arcellx ACLX, for $115 per ...
Gilead Sciences, Inc. shares have risen more than 43% over the past year. Click here to find out why GILD stock is a Sell.
Gilead Sciences (NASDAQ:GILD) gains attention within the nasdaq composite following disclosure and steady performance signals ...
Despite a recent FDA clinical hold on its HIV treatment trials (GS-1720 and GS-4182) due to a decrease in CD4+ T-cells, Gilead Sciences (NASDAQ:GILD) has shown strong performance this year. Its stock ...
Detailed price information for Gilead Sciences Inc (GILD-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results